History | Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 153 KB)

Published:

11 January 2023
Register of interests (PDF 163 KB)

Published:

11 January 2023

Final draft guidance

Final draft guidance
Final appraisal document (PDF 238 KB)

Published:

30 November 2022
Committee papers (PDF 2.38 MB)

Published:

30 November 2022

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) (PDF 283 KB)

Published:

18 August 2022
Appraisal consultation document (online commenting)
Committee papers (PDF 10.06 MB)

Published:

18 August 2022
Public committee slides (PDF 1.69 MB)

Published:

18 August 2022

Assessment report sent for information

Assessment report (PDF 5.68 MB)

Published:

08 June 2022

Assessment report sent for information

Final protocol (PDF 920 KB)

Published:

11 November 2021

Invitation to participate

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 292 KB)

Published:

04 October 2021
Final stakeholder list (PDF 164 KB)

Published:

04 October 2021
Final scope (PDF 231 KB)

Published:

04 October 2021
Equality impact assessment (Scoping) (PDF 120 KB)

Published:

04 October 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 251 KB)

Published:

23 October 2020
Draft matrix post referral (PDF 162 KB)

Published:

23 October 2020